A Cost-Utility Analysis of the Risk Model-Guided Antiemetic Prophylaxis Versus Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer- A Net-Benefit Regression Approach
Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.08.744
https://www.valueinhealthjournal.com/article/S1098-3015(16)33859-1/fulltext
Section Title :
Disease-Specific Studies
Section Order :
2742
First Page :
A890
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33859-1&doi=10.1016/j.jval.2016.08.744